NO954329L - Forbedrede farmasöytisk akseptable blandinger inneholdende en alkohol og et hydrofobt legemiddel - Google Patents

Forbedrede farmasöytisk akseptable blandinger inneholdende en alkohol og et hydrofobt legemiddel

Info

Publication number
NO954329L
NO954329L NO954329A NO954329A NO954329L NO 954329 L NO954329 L NO 954329L NO 954329 A NO954329 A NO 954329A NO 954329 A NO954329 A NO 954329A NO 954329 L NO954329 L NO 954329L
Authority
NO
Norway
Prior art keywords
alcohol
hydrophobic drug
pharmaceutically acceptable
compositions containing
acceptable compositions
Prior art date
Application number
NO954329A
Other languages
English (en)
Norwegian (no)
Other versions
NO954329D0 (no
Inventor
Bernard Charles Sherman
Original Assignee
Bernard Charles Sherman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bernard Charles Sherman filed Critical Bernard Charles Sherman
Publication of NO954329D0 publication Critical patent/NO954329D0/no
Publication of NO954329L publication Critical patent/NO954329L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO954329A 1993-04-28 1995-10-27 Forbedrede farmasöytisk akseptable blandinger inneholdende en alkohol og et hydrofobt legemiddel NO954329L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ247516A NZ247516A (en) 1993-04-28 1993-04-28 Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant
PCT/CA1994/000222 WO1994025068A1 (en) 1993-04-28 1994-04-22 Improved pharmaceutical acceptable compositions containing an alcohol and a hydrophobic drug

Publications (2)

Publication Number Publication Date
NO954329D0 NO954329D0 (no) 1995-10-27
NO954329L true NO954329L (no) 1995-12-21

Family

ID=19924336

Family Applications (1)

Application Number Title Priority Date Filing Date
NO954329A NO954329L (no) 1993-04-28 1995-10-27 Forbedrede farmasöytisk akseptable blandinger inneholdende en alkohol og et hydrofobt legemiddel

Country Status (19)

Country Link
US (1) US5843891A (de)
EP (1) EP0696920B1 (de)
JP (1) JPH08509475A (de)
CN (1) CN1124457A (de)
AT (1) ATE173635T1 (de)
AU (1) AU677660B2 (de)
BR (1) BR9406513A (de)
CA (1) CA2160880A1 (de)
CZ (1) CZ276995A3 (de)
DE (1) DE69414840T2 (de)
FI (1) FI955091A7 (de)
HU (1) HUT73664A (de)
IL (1) IL109401A0 (de)
MX (1) MX9402922A (de)
NO (1) NO954329L (de)
NZ (1) NZ247516A (de)
PL (1) PL311294A1 (de)
WO (1) WO1994025068A1 (de)
ZA (1) ZA942803B (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
CZ301382B6 (cs) * 1997-03-12 2010-02-10 Abbott Laboratories Chad377/Ap6D-2 Hydrofilní binární systémy pro podávání cyklosporinu
US6258783B1 (en) 1997-04-29 2001-07-10 Bernard Charles Sherman Emulsion preconcentrate comprising a cyclosporin and acetylated monoglyceride
NZ314702A (en) * 1997-04-29 1998-07-28 Bernard Charles Sherman Pharmaceutical composition comprising a cyclosporin in a solvent system of acetylated monoglycerides and a surfactant and optionally a hydrophilic solvent
FR2764509A1 (fr) * 1997-06-11 1998-12-18 Debiopharm Sa Compositions pharmaceutiques contenant du dichlorhydrate de cinchonine
KR100587551B1 (ko) 1997-12-10 2006-06-08 싸이클로스포린 테라퓨틱스 리미티드 오메가-3 지방산 오일을 함유하는 약학 조성물
US20030216303A1 (en) * 1998-03-06 2003-11-20 Michael Ambuhl Emulsion preconcentrates containing cyclosporin or a macrolide
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
US7258869B1 (en) * 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US20030157170A1 (en) * 2001-03-13 2003-08-21 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
US20030054036A1 (en) * 2001-03-13 2003-03-20 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
DK1392254T3 (da) 2001-04-20 2007-07-02 Univ British Columbia Micelle-lægemiddelindgivelsessystem for hydrofobe lægemidler
US6592899B2 (en) 2001-10-03 2003-07-15 Macromed Incorporated PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water
PT1435910E (pt) * 2001-10-19 2009-09-07 Isotechnika Inc Novos pré-concentrados de microemulsão de análogos da ciclosporina
WO2003053404A1 (en) * 2001-12-20 2003-07-03 Bernard Charles Sherman Pharmaceutical compositions comprising a cyclosporin, a hydrophilic surfactant and a lipophilic surfactant
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
WO2005053727A2 (en) * 2003-11-29 2005-06-16 Sangstat Medical Corporation Pharmaceutical compositions for bioactive peptide agents
US7151085B2 (en) * 2004-11-15 2006-12-19 Allergan, Inc. Therapeutic methods using cyclosporine components
US7135455B2 (en) * 2004-11-15 2006-11-14 Allergan, Inc Methods for the therapeutic use of cyclosporine components
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US20080233053A1 (en) * 2005-02-07 2008-09-25 Pharmalight Inc. Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
WO2007140416A2 (en) 2006-05-30 2007-12-06 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
PT2359808E (pt) 2006-08-09 2013-08-28 Intarcia Therapeutics Inc Sistemas de entrega osmótica e montagens de pistão
TWI394564B (zh) * 2006-09-21 2013-05-01 Alcon Res Ltd 自行保存型水性藥學組成物
ES2402172T3 (es) 2007-04-23 2013-04-29 Intarcia Therapeutics, Inc Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
WO2009042114A2 (en) 2007-09-21 2009-04-02 The Johns Hopkins University Phenazine derivatives and uses thereof
AU2008310956B2 (en) 2007-10-08 2014-08-07 Aurinia Pharmaceuticals Inc. Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US8906414B1 (en) 2009-04-27 2014-12-09 University Of South Florida Methods and compositions for improving bioavailability of epigallocatechin gallate (EGCG)
MX338355B (es) 2009-06-09 2016-04-13 Aurinia Pharmaceuticals Inc Sistemas de suministro de farmaco topico para uso oftalmico.
EP3735944A1 (de) 2009-09-28 2020-11-11 Intarcia Therapeutics, Inc. Schnelle initiierung und/oder beendigung der verabreichung substantiell stabiler arzneimittel
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
KR101211902B1 (ko) * 2012-04-30 2012-12-13 주식회사 휴온스 사이클로스포린 함유 무자극성 나노에멀젼 안약 조성물
ES2948387T3 (es) 2012-08-24 2023-09-11 Sun Pharmaceutical Ind Ltd Formulación oftálmica de ácidos grasos polioxílicos o lípidos polioxílicos y tratamiento de afecciones oculares
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US10016363B2 (en) 2014-09-18 2018-07-10 Virun, Inc. Pre-spray emulsions and powders containing non-polar compounds
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
KR102650751B1 (ko) 2015-06-03 2024-03-22 인타르시아 세라퓨틱스 인코포레이티드 임플란트 배치 및 제거 시스템들
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
DK3373976T3 (da) 2015-11-10 2024-04-02 Sun Pharmaceutical Ind Ltd Topiske formuleringer og anvendelser deraf
PT3423076T (pt) 2016-02-29 2024-07-01 Sun Pharmaceutical Ind Ltd Formulações tópicas contendo ciclosporina e respetivas utilizações
CN109310743A (zh) 2016-05-16 2019-02-05 因塔西亚制药公司 胰高血糖素受体选择性多肽及其使用方法
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
EP3824296A4 (de) 2018-07-20 2022-04-27 Lipocine Inc. Lebererkrankung
JP2026027576A (ja) * 2022-11-22 2026-02-19 一丸ファルコス株式会社 Ｒａｓ阻害ペプチドを含む組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS498246B1 (de) * 1965-07-15 1974-02-25
JPS5919525B2 (ja) * 1976-09-03 1984-05-07 武田薬品工業株式会社 注射剤
FI65914C (fi) * 1978-03-07 1984-08-10 Sandoz Ag Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
GB8903804D0 (en) * 1989-02-20 1989-04-05 Sandoz Ltd Improvements in or relating to organic compounds
JPS6226220A (ja) * 1985-07-29 1987-02-04 Hishiyama Seiyaku Kk ケトプロフエン注射液
JP2577049B2 (ja) * 1987-06-04 1997-01-29 三共株式会社 シクロスポリン製剤
CH679119A5 (de) * 1988-05-13 1991-12-31 Sandoz Ag
KR0148748B1 (ko) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
HU208491B (en) * 1990-11-27 1993-11-29 Gyogyszerkutato Intezet Process for producing oral pharmaceutical composition containing cyclosporin
GB9113872D0 (en) * 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
JPH0558906A (ja) * 1991-09-06 1993-03-09 Sankyo Co Ltd シクロスポリン点眼製剤

Also Published As

Publication number Publication date
FI955091L (fi) 1995-12-14
EP0696920B1 (de) 1998-11-25
MX9402922A (es) 1997-05-31
HUT73664A (en) 1996-09-30
HU9503075D0 (en) 1995-12-28
ATE173635T1 (de) 1998-12-15
US5843891A (en) 1998-12-01
CA2160880A1 (en) 1994-11-10
IL109401A0 (en) 1994-11-28
WO1994025068A1 (en) 1994-11-10
AU677660B2 (en) 1997-05-01
EP0696920A1 (de) 1996-02-21
AU6673494A (en) 1994-11-21
PL311294A1 (en) 1996-02-05
CN1124457A (zh) 1996-06-12
ZA942803B (en) 1996-01-22
CZ276995A3 (en) 1996-03-13
FI955091A7 (fi) 1995-12-14
FI955091A0 (fi) 1995-10-25
NO954329D0 (no) 1995-10-27
BR9406513A (pt) 1996-01-09
DE69414840D1 (de) 1999-01-07
NZ247516A (en) 1995-02-24
JPH08509475A (ja) 1996-10-08
DE69414840T2 (de) 1999-04-22

Similar Documents

Publication Publication Date Title
NO954329L (no) Forbedrede farmasöytisk akseptable blandinger inneholdende en alkohol og et hydrofobt legemiddel
KR950007841A (ko) 트라마돌 염을 함유하는 서방성 약물 제제
NO952269L (no) Stabiliserte medisinske aerosollösnings-formuleringer
NO964813D0 (no) Fremgangsmåte for stabilisering av duocarmycinderivater
ES2161291T3 (es) N-(indol-2-carbonil)amidas y derivados como inhibidores de la glucogeno fosforilasa.
KR940005270A (ko) 뼈 손실 예방에 유용한 벤조티오펜
BR9909796A (pt) Composição farmacêutica
ES2154650T3 (es) Composicion que comprende una formulacion con factor de coagulacion viii, procedimiento para su preparacion y uso de un tensioactivo como estabilizador.
BR9509019A (pt) Processo para fabricar unidades de dosagem farmacêutica e comprimido isento de solventes orgânicos
ES2083668T3 (es) Combinaciones antiviricas que contienen analogos de nucleosidos.
DE59202280D1 (de) Antiphlogistisches Mittel.
MX9204637A (es) Nuevos derivados de pirazina y procedimiento para su preparacion.
ES2017264A6 (es) Un metodo para controlar las incrustaciones biologicas en un sistema acuoso.
PT96381A (pt) Processo para a preparacao de derivados de 2-aminopirimidina-4-carboxamida e de composicoes farmaceuticas que os contem
ES2173883T3 (es) Utilizacion de derivados de piperacina-acetamida contra los daños de reperfusion.
AU4419497A (en) Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form
KR940013497A (ko) 소염진통겔 제제
KR950007857A (ko) 경구투여용 라파마이신 제제
ES2132241T3 (es) Composiciones oftalmicas y metodos para su conservacion y su empleo.
CS261206B2 (en) Isotonization and stabilization agent
ES2310550T3 (es) Preparacion liquida acuosa de pranoprofeno.
KR970704455A (ko) 인터류킨 5 생성 억제제(Interleukin 5 Production Inhibitor)
US4406888A (en) Aqueous micellar solutions of levonantradol and N-methyllevonantradol and lyophilic forms thereof for reconstitution
NO20063208L (no) UV-stabil, flytende eller halvfast transdermal administrasjonsform omfattende en lysomfintlig aktiv ingrediens
KR960033450A (ko) 6,7-치환-2- 아미노테트랄린을 함유한 패혈증 쇼크 치료용 및 해열, 소염용 의약 조성물